0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Pharmaceutical Overdose Deaths, United States, 2010 FREE

Christopher M. Jones, PharmD; Karin A. Mack, PhD; Leonard J. Paulozzi, MD
[+] Author Affiliations

Author Affiliations: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, Georgia (fjr0@cdc.gov).


Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

More Author Information
JAMA. 2013;309(7):657-659. doi:10.1001/jama.2013.272.
Text Size: A A A
Published online

To the Editor: Data recently released by the National Center for Health Statistics show drug overdose deaths increased for the 11th consecutive year in 2010.1 Pharmaceuticals, especially opioid analgesics, have driven this increase.2 Other pharmaceuticals are involved in opioid overdose deaths, but their involvement is less well characterized. Using 2010 mortality data, we describe the specific drugs involved in pharmaceutical and opioid-related overdose deaths.

Data are from the National Vital Statistics System multiple cause-of-death file, which is based on death certificates submitted by medical examiners or coroners.1 Drug overdose deaths were those assigned an underlying cause of death using the International Classification of Diseases, Tenth Revision (ICD-10) codes X40-X44 (unintentional), X60-X64 (suicide), X85 (homicide), and Y10-Y14 (undetermined intent). Pharmaceutical-related overdose deaths were those assigned specific ICD-10 codes T36-T39, T40.2-T40.4, T41-T43.5, and T43.8-T50.8; psychotherapeutic and central nervous system pharmaceuticals were defined as T40.2-T40.4, T42, T43.0-T43.5, T43.8, T43.9; and opioid analgesics were those assigned codes T40.2-T40.4. Pharmaceutical deaths by this definition are predominately due to prescription drugs; a small minority involve over-the-counter or illicit drugs combined with prescription drugs in the same ICD-10 T codes. Institutional review board approval was waived because no personal identifiers were involved.

In 2010, there were 38 329 drug overdose deaths in the United States; most (22 134; 57.7%) involved pharmaceuticals; 9429 (24.6%) involved only unspecified drugs. Of the pharmaceutical-related overdose deaths, 16 451 (74.3%) were unintentional, 3780 (17.1%) were suicides, and 1868 (8.4%) were of undetermined intent. Opioids (16 651; 75.2%), benzodiazepines (6497; 29.4%), antidepressants (3889; 17.6%), and antiepileptic and antiparkinsonism drugs (1717; 7.8%) were the pharmaceuticals (alone or in combination with other drugs) most commonly involved in pharmaceutical overdose deaths (Table). Among overdose deaths involving opioid analgesics, the pharmaceuticals most often also involved in these deaths were benzodiazepines (5017; 30.1%), antidepressants (2239; 13.4%), antiepileptic and antiparkinsonism drugs (1125; 6.8%), and antipsychotics and neuroleptics (783; 4.7%).

Table Graphic Jump LocationTable. Specific Drug Involvement in Pharmaceutical Overdose Deaths, United States, 2010

Opioids were frequently implicated in overdose deaths involving other pharmaceuticals. They were involved in the majority of deaths involving benzodiazepines (77.2%), antiepileptic and antiparkinsonism drugs (65.5%), antipsychotic and neuroleptic drugs (58.0%), antidepressants (57.6%), other analgesics, antipyretics, and antirheumatics (56.5%), and other psychotropic drugs (54.2%). Among overdose deaths due to psychotherapeutic and central nervous system pharmaceuticals, the proportion involving only a single class of such drugs was highest for opioids (4903/16 651; 29.4%) and lowest for benzodiazepines (239/6497; 3.7%) (Figure).

Place holder to copy figure label and caption
Figure. Percentage of Overdose Deaths for Specific Psychotherapeutic and Central Nervous System (CNS) Pharmaceuticals That Involved Only a Single Drug Class, United States, 2010
Graphic Jump Location

Death certificate data have limitations,3 but they are the sole source for detailed death information at the national level. This analysis is limited by the 25% of death certificates in which the type of drugs involved was not specified, an omission due to lack of toxicological testing or failure to record the results of such tests on the death certificate. Therefore, the numbers reported in this analysis are undercounts. Additionally, the degree to which drugs are specified on death certificates might vary across the United States and therefore differentially undercount types of drugs more common in areas in which death certificates are less complete. This might affect the ranking of some pharmaceuticals in the Table.

This analysis confirms the predominant role opioid analgesics play in pharmaceutical overdose deaths, either alone or in combination with other drugs. It also, however, highlights the frequent involvement of drugs typically prescribed for mental health conditions such as benzodiazepines, antidepressants, and antipsychotics in overdose deaths. People with mental health disorders are at increased risk for heavy therapeutic use, nonmedical use, and overdose of opioids.46 Screening, identification, and appropriate management of such disorders is an important part of both behavioral health and chronic pain management. Tools such as prescription drug monitoring programs and electronic health records can help clinicians to identify risky medication use and inform treatment decisions, especially for opioids and benzodiazepines.

Author Contributions: Dr Jones had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Jones, Paulozzi.

Acquisition of data: Jones.

Analysis and interpretation of data: Jones, Mack, Paulozzi.

Drafting of the manuscript: Jones.

Critical revision of the manuscript for important intellectual content: Jones, Mack, Paulozzi.

Statistical analysis: Jones.

Administrative, technical, or material support: Mack, Paulozzi.

Study supervision: Jones.

Conflict of Interest: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: The US Centers for Disease Control and Prevention funded this study.

Role of the Sponsor: The US Centers for Disease Control and Prevention supported the staff responsible for the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official position of the US Centers for Disease Control and Prevention.

Centers for Disease Control and Prevention.  National Vital Statistics System. 2010 Multiple Cause of Death File. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2012
Paulozzi LJ, Jones C, Mack K, Rudd R.Centers for Disease Control and Prevention (CDC).  Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008.  MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492
PubMed
Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data.  Drug Saf. 2007;30(6):533-540
PubMed   |  Link to Article
Edlund MJ, Martin BC, Fan MY, Braden JB, Devries A, Sullivan MD. An analysis of heavy utilizers of opioids for chronic noncancer pain in the TROUP study.  J Pain Symptom Manage. 2010;40(2):279-289
PubMed   |  Link to Article
Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates.  Drug Alcohol Depend. 2008;94(1-3):38-47
PubMed   |  Link to Article
Bohnert AS, Valenstein M, Bair MJ,  et al.  Association between opioid prescribing patterns and opioid overdose-related deaths.  JAMA. 2011;305(13):1315-1321
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure. Percentage of Overdose Deaths for Specific Psychotherapeutic and Central Nervous System (CNS) Pharmaceuticals That Involved Only a Single Drug Class, United States, 2010
Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Specific Drug Involvement in Pharmaceutical Overdose Deaths, United States, 2010

References

Centers for Disease Control and Prevention.  National Vital Statistics System. 2010 Multiple Cause of Death File. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2012
Paulozzi LJ, Jones C, Mack K, Rudd R.Centers for Disease Control and Prevention (CDC).  Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008.  MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492
PubMed
Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data.  Drug Saf. 2007;30(6):533-540
PubMed   |  Link to Article
Edlund MJ, Martin BC, Fan MY, Braden JB, Devries A, Sullivan MD. An analysis of heavy utilizers of opioids for chronic noncancer pain in the TROUP study.  J Pain Symptom Manage. 2010;40(2):279-289
PubMed   |  Link to Article
Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates.  Drug Alcohol Depend. 2008;94(1-3):38-47
PubMed   |  Link to Article
Bohnert AS, Valenstein M, Bair MJ,  et al.  Association between opioid prescribing patterns and opioid overdose-related deaths.  JAMA. 2011;305(13):1315-1321
PubMed   |  Link to Article
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 57

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles